phosphorylcholine has been researched along with Diarrhea in 6 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle." | 9.19 | A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014) |
| "There is still no effective treatment for cryptosporidiosis even though the disease has a significant impact on HIV-infected adults and children." | 6.76 | In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. ( Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E, 2011) |
| "Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle." | 5.19 | A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014) |
| "There is still no effective treatment for cryptosporidiosis even though the disease has a significant impact on HIV-infected adults and children." | 2.76 | In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. ( Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E, 2011) |
| "Oral perifosine was tolerable up to 600mg/week in cancer patients when administered with meal and prophylactic antiemetics." | 2.75 | First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ( Berdel, W; Engel, J; Hanauske, AR; Mross, K; Sindermann, H; Unger, C, 2010) |
| "Diarrhea is characterized by alterations in the gut microbiota, metabolites, and host response to these changes." | 1.91 | Colonic phosphocholine is correlated with Candida tropicalis and promotes diarrhea and pathogen clearance. ( Chen, J; Guan, G; He, Y; Huang, C; Liang, J; Peng, C; Xiong, X; Yin, J; Yin, Y; Zhou, X, 2023) |
| "Miltefosine is an oral drug which was used as a topical application for skin metastasis of breast cancer." | 1.43 | Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. ( Das Gupta, RK; Das, P; Dhariwal, AC; Pandey, K; Ravidas, V; Siddiqui, NA; Singh, TP; Sinha, SK; Verma, RB, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, X | 1 |
| He, Y | 1 |
| Chen, J | 1 |
| Xiong, X | 1 |
| Yin, J | 1 |
| Liang, J | 1 |
| Peng, C | 1 |
| Huang, C | 1 |
| Guan, G | 1 |
| Yin, Y | 1 |
| Figg, WD | 1 |
| Monga, M | 1 |
| Headlee, D | 1 |
| Shah, A | 1 |
| Chau, CH | 1 |
| Peer, C | 1 |
| Messman, R | 1 |
| Elsayed, YA | 1 |
| Murgo, AJ | 1 |
| Melillo, G | 1 |
| Ryan, QC | 1 |
| Kalnitskiy, M | 1 |
| Senderowicz, AM | 1 |
| Hollingshead, M | 1 |
| Arbuck, SG | 1 |
| Sausville, EA | 1 |
| Pandey, K | 1 |
| Ravidas, V | 1 |
| Siddiqui, NA | 1 |
| Sinha, SK | 1 |
| Verma, RB | 1 |
| Singh, TP | 1 |
| Dhariwal, AC | 1 |
| Das Gupta, RK | 1 |
| Das, P | 1 |
| Unger, C | 1 |
| Berdel, W | 1 |
| Hanauske, AR | 1 |
| Sindermann, H | 1 |
| Engel, J | 1 |
| Mross, K | 1 |
| Sinkala, E | 1 |
| Katubulushi, M | 1 |
| Sianongo, S | 1 |
| Obwaller, A | 1 |
| Kelly, P | 1 |
| Sundar, S | 1 |
| Makharia, A | 1 |
| More, DK | 1 |
| Agrawal, G | 1 |
| Voss, A | 1 |
| Fischer, C | 1 |
| Bachmann, P | 1 |
| Murray, HW | 1 |
4 trials available for phosphorylcholine and Diarrhea
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Area Under Curve; Diarrhea; Disease | 2014 |
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
Topics: Abdominal Pain; Administration, Oral; Antiemetics; Antineoplastic Agents; Diarrhea; Dose-Response Re | 2010 |
In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptosporidiosis; Diarrhea; Early Termination of Clin | 2011 |
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; H | 2000 |
2 other studies available for phosphorylcholine and Diarrhea
| Article | Year |
|---|---|
Colonic phosphocholine is correlated with Candida tropicalis and promotes diarrhea and pathogen clearance.
Topics: Animals; Candida tropicalis; Colon; Diarrhea; Mice; Mice, Knockout; Phosphorylcholine; Reactive Oxyg | 2023 |
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate | 2016 |